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Background: Coronary collateral circulation plays an important role to protect myocardium from ischemia, preserve
myocardial contractility and reduce cardiovascular events. Chronic kidney disease (CKD) is associated with poor
coronary collateral development and cardiovascular outcome. However, limited research investigates the predictors
for collateral development in the CKD population.
Methods: We evaluated 970 consecutive patients undergoing coronary angiography and 202 patients with CKD,
defined as a glomerular filtration rate less than 60 ml/min/1.73 m2, were finally analyzed. The collateral scoring
system developed by Rentrop was used to classify patients into poor (grades 0 and 1) or good (grades 2 and 3)
collateral group.
Results: The patients with poor collateral (n = 122) had a higher incidence of hypertension (82% vs 63.8%,
p = 0.005), fewer diseased vessels numbers (2.1 ± 0.9 vs 2.6 ± 0.6, p < 0.001) and a trend to be diabetic (56.6% vs.
43.8%, p = 0.085) or female sex (37.7% vs. 25.0%, p = 0.067). Multivariate analysis showed hypertension (odd ratio
(OR) 2.672, p = 0.006), diabetes (OR 1.956, p = 0.039) and diseased vessels numbers (OR 0.402, p < 0.001) were
significant predictors of poor coronary collaterals development. Furthermore, hypertension and diabetes have a
negative synergistic effect on collateral development (p = 0.004 for interaction).
Conclusions: In the CKD population hypertension and diabetes might negatively influence the coronary collaterals
development.
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Chronic kidney disease (CKD) is a worldwide public
health problem with increased morbidity and mortality
[1]. Two major poor outcomes of CKD are progression
to end-stage renal disease and development of cardiovas-
cular disease (CVD) [2]. CVD is the leading cause of
morbidity and mortality in CKD patients [3]. The major
risk factors in this patient group are contributed to trad-
itional risk factors and non-traditional risk factors such
as hypertension, diabetes, arterial stiffness, and so on* Correspondence: lth@kmu.edu.tw
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reproduction in any medium, provided the or[4,5]. Structural and functional abnormalities of heart
are also another possible issues associated with excess
cardiovascular risk [6,7].
The development of coronary collaterals is an adap-
tive response to chronic myoischemia and serves as a
conduit bridging the significantly stenotic coronary
vessels [8,9]. Collateral circulation can protect and pre-
serve myocardium from episodes of ischemia, enhance
residual myocardial contractility, and reduce angina
symptoms and cardiovascular events [10-12]. However,
there is inter-individual difference of coronary collat-
eral formation and the mechanisms for the different
individual ability to develop collateral circulation are
still unclear. Chronic kidney disease is associated with
poor coronary collateral vessel development in the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cussing about the predictors of poor collaterals in the
CKD population with significant coronary artery dis-
ease (SCAD). Therefore, we conducted this study for
further survey.Methods
Study subjects
From February 2002 to March 2008, we screened 970
consecutive patients who underwent diagnostic coron-
ary angiography at Kaohsiung Medical University Hos-
pital in Taiwan. Then we excluded patients with
coronary artery lumen diameter stenosis <70%, esti-
mated glomerular filtration rate (eGFR) ≧60 ml/min/
1.73 m2, history of coronary artery bypass surgery
(CABG), history of percutaneous coronary intervention
(PCI), or inadequate angiograms for collateral evalu-
ation. Finally 202 patients were analyzed in this study.
CKD was defined as glomerular filtration rate <60 ml/
min/1.73 m2. The value of eGFR was calculated using
the equation in the Modification of Diet in Renal Dis-
ease study [15]. Other analyzed demographic and base-
line data included gender, age, duration of chest pain,
history of diabetes mellitus, hypertension, hypercholes-
terolemia, cigarette smoking, and medications. Duration
of chest pain was defined as the time between the first
occurrence of symptoms until the day of diagnostic cor-
onary angiography. The research protocol was approved
and registered by the ethics committee (Kaohsiung
Medical University Hospital- Institutional Review
Board) at our institution, and informed consent was
obtained from all patients.Coronary angiography
The coronary artery angiography films were reviewed by
two experienced cardiologists blind to patients’ clinical
characteristics. A third reviewer blinded to the readings
of the first two reviewers served as arbitrator of differ-
ences. Coronary angiography was performed by the fem-
oral or radial approach with 6Fr diagnostic catheters.
Images were recorded in multiple projections for left
and right coronary arteries. Coronary artery stenosis was
determined by quantitative coronary angiography. The
presence of coronary artery disease (CAD) is defined as
coronary diameter stenosis more than 50%. Vessels exhi-
biting a 70% or greater reduction in lumen area were
classified as significant lesion. The recorded data also
included the location, number and percentage of sten-
osis of diseased vessels, the vessel to which the collat-
erals were connected, the grade of coronary collateral
circulation, and the coronary artery disease severity
scoring.Collateral scoring and pathways evaluation by coronary
angiography
In subjects with more than one SCAD vessel, the ves-
sel with the highest collateral grade was chosen for
analysis. The collateral scoring system developed by
Rentrop and Cohen was used [16]. Grades of collateral
filling from the contralateral vessel were: 0 = none;
1 = filling of side branches of the artery to be dilated
via collateral channels without visualization of the epi-
cardial segment; 2 = partial filling of the epicardial seg-
ment via collateral channels; 3 = complete filling of the
epicardial segment of the artery being dilated via col-
lateral channels. In subjects with more than one collat-
eral vessel supplying the distal aspect of the diseased
artery, the highest collateral grade was recorded.
Patients were then classified according to their collat-
eral grades as either poor (grade 0 or grade 1 collat-
eral) or good (grade 2 or grade 3 collateral). In
addition, the size of the collateral connection (CC)
diameter was assessed by 3 grades: CC grade 0, no
continuous connection between donor and recipient
artery; CC grade 1, continuous, threadlike connection,
and CC grade 2, continuous, small side branch-like
size of the collateral throughout its course [17]. In the
case of coexisting collateral connections, the prominent
one was defined as the principal. The anatomic path-
ways were categorized according to Levin's pathways
and summarized in 4 categories: septal, intra-arterial
(bridging), epicardial with proximal takeoff (atrial
branches), and epicardial with distal takeoff [18,19]. In
the case of coexisting collateral pathways, the principal
pathway was defined as the one that was the first to
opacify the stenotic epicardial segments.Coronary artery disease severity scoring by coronary
angiography
We evaluated the extent of coronary artery athero-
sclerosis by a “diffuse score” (DS) developed by Negri
et al. and modified by Birnie et al. [20,21]. In brief,
the coronary circulation is divided into 15 segments,
and 8 of them are classified as first-order segments:
proximal and middle right coronary arteries, left
main coronary artery, proximal, middle, and distal
left anterior descending, and proximal and distal cir-
cumflex. There are 7 second-order segments: distal
right coronary artery, posterior descending branch,
obtuse marginal branch, postero-lateral branch of cir-
cumflex, and the first 2 diagonal branches of the left
anterior descending artery. The first-order segments
receive a score of 1 and the second order segments
scored 0.5. The overall diffuse score is the sum of
the individual segment scores and the maximum
score is 11.5.
Table 1 Baseline characteristics in patients with poor and
good collateral
Variables Poor collateral Good collateral P value
(n = 122) (n = 80)
Age (years) 68.1 ± 10.1 65.7 ± 12.0 0.146
Gender (Female, %) 37.7 25.0 0.067
DM (%) 56.6 43.8 0.085
HTN (%) 82 63.8 0.005
Smoking (%) 50 42.5 0.316
BMI 25.0 ± 4.0 25.5 ± 3.6 0.351
eGFR (mL/min/1.73 m2) 40.7 ± 16.5 40.3 ± 16.0 0.853
Previous events of ACS (%) 68 58.8 0.229
Laboratory data
Hemoglobin (g/dl) 12.2 ± 2.3 12.2 ± 2.6 1.000
Cholesterol (mg/dl) 198.5 ± 41.8 212.4 ± 67.8 0.104
Triglyceride (mg/dl) 187.7 ± 142.3 168.6 ± 138.1 0.360
Uric acid (mg/dl) 7.1 ± 2.2 6.9 ± 2.0 0.713
Medication
Anti-platelet (%) 43.4 51.3 0.314
ACEI (%) 19.8 21.3 % 0.855
ARB (%) 21.6 24.0 0.725
Beta blocker (%) 30.8 34.7 0.636
Nitrate (%) 24.8 30.7 0.407
CCB (%) 25 17.3 0.283
Diuretic (%) 21.6 24.0 0.725
Statin (%) 18.6 27.6 0.159
ACEI: angiotensin converting enzyme inhibitor; ACS: acute coronary syndrome;
ARB: angiotensin II receptor blocker; BMI: body mass index; CCB: calcium
channel blocker; DM: diabetes; HTN: hypertension; eGFR: estimated glomerular
filtration rate.
Table 2 Angiographic characteristics in patients with
poor and good collateral
Mean± SD Poor collateral Good collateral P value
Number (%) (n = 122) (n = 80)
Number of diseased vessels 2.1 ± 0.9 2.6 ± 0.6 <0.001
Significant CAD, n (%)
1 vessel disease (%) 47 (38.5) 12 (15.0)
2 vessel disease (%) 41 (33.6) 21 (26.3) <0.001
3 vessel disease (%) 34 (27.9) 47 (58.8)
Diffuse score of CAD 3.01 ± 1.75 4.03 ± 1.83 <0.001
1 vessel disease 1.25 ± 0.67 1.42 ± 0.66
2 vessel disease 2.72 ± 0.86 2.84 ± 0.99
3 vessel disease 4.41 ± 1.43 4.84 ± 1.63
CAD: coronary artery disease.
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All data were expressed as means ± standard deviation.
Independent t test was used to compare continuous
variables between the two groups. Chi-square test was
used to compare categorical data. The linear-by-linear
association analysis was used to test variables interaction
on the collateral development. Subsequently, signifi-
cantly correlated variables in the univariate analysis or
relevant variables were further analyzed by multivariate
logistic regression analysis to predict the collateral devel-
opment (poor vs. good). All p values were two-sided
with a significance level of p < .05. The Statistical Pack-
age for the Social Sciences 11.0 for Windows (SPSS Inc.,
Chicago, IL) was used for statistical analysis.
Results
Clinical characteristics
Among the 970 subjects initially evaluated, 768 patients
were excluded for the following reasons: coronary artery
lumen diameter stenosis <70%, eGFR ≧60 ml/min/
1.73 m2, history of CABG or PCI, or inadequate angio-
grams for collateral evaluation. The final study popula-
tion was 202 subjects (136 male and 66 female; average
age, 67.2 ± 10.9 years old). For SCAD, 59 patients
(29.2%) are 1VD, 62 patients (30.7%) are 2VD, and 81
patients (40.1%) are 3VD. The overall eGFR is
40.5 ± 16.3 ml/min/1.73 m2. 153 patients (75.7%) are
CKD stage 3, 22 patients (10.9%) are CKD stage 4, and
27 patients (13.4%) are CKD stage 5.
Coronary collaterals
The 2 collaterals readers obtained a 96% agreement in
the collateral classifications. Of the 202 patients en-
rolled, 86 (42.6%) patients had no coronary collaterals.
In subjects with collaterals, the Rentrop coronary grade
was distributed as follows: 36 (17.8%) with grade 1, 60
(29.7%) with grade 2 and 20 (9.9%) with grade 3. Fur-
thermore, we also used CC grade to provide additional
information for the size of collateral connection diam-
eter: CC grade 0 was observed in 49.5%, CC grade 1 in
37.1%, and CC grade 2 in 13.4%. For the collateral path-
ways: the principal pathways was through septal connec-
tions in 51.3%, atrial-epicardial connections in 26.1%,
bridging connections in 13%, and distal inter-arterial
connections in 9.6%. In addition, there was no signifi-
cant difference between collateral grades in different
CKD stages (p = 0.790).
Baseline characteristics in patients with poor and good
collateral were shown in the Table 1, the patients with
poor collateral (n = 122) had a higher incidence of hyper-
tension (82% vs 63.8%, p = 0.005), and a trend to be fe-
male sex (37.7% vs. 25.0%, p = 0.067) or diabetic (56.6%
vs. 43.8%, p = 0.085). Angiographic characteristics in
patients with poor and good collateral were shown inthe Table 2, the patients with poor collateral had a fewer
diseased vessels numbers (2.1 ± 0.9 vs 2.6 ± 0.6,
p < 0.001), and lower severity score of CAD (3.01 ± 1.75
vs 4.03 ± 1.83, p < 0.001).
Hsu et al. BMC Nephrology 2012, 13:98 Page 4 of 7
http://www.biomedcentral.com/1471-2369/13/98Logistic regression analysis
Age, sex, body mass index (BMI), history of diabetes,
history of hypertension, history of dyslipidemia, and
number of diseased vessels were included in our univari-
ate analysis. Age, sex, significant correlated variables and
relevant variables such as history of diabetes were fur-
ther analyzed by multivariate logistic regression analysis.
We found diabetes (p = 0.039, OR= 1.956, 95% CI = 1.04-
3.70), hypertension (p = 0.006, OR= 2.672, 95% CI = 1.32-
5.40), and number of diseased vessels (p < 0.001, OR=
0.402, 95% CI = 0.26-0.62) were significant independent
predictors of poor coronary collaterals development
(Table 3).
Furthermore, diabetes and hypertension were also the
most common causes of CKD, so we further analyzed
the combined risk between them and found there was a
synergistic effect of diabetes and hypertension on the
poor coronary collateral formation (p = 0.004 for inter-
action; Table 4). In patients who have only diabetes or
hypertension, the risk of poor collateral formation did
not significantly increase (OR 1.42, 95% CI: 0.63-3.19;
p = 0.395). However, when patients have both diabetes
and hypertension, there is a 3.10-fold risk of poor collat-
eral development (OR 3.10, 95% CI: 1.35-7.12; p = 0.008).
Discussion
In the current study, we surveyed the predictor of poor
coronary collaterals in 202 Chinese CKD patients and
found there were three major findings. First, high per-
centages of CKD patients (42.6%) with significant coron-
ary artery disease have no coronary collaterals. Second,
hypertension and diabetes are significantly independent
predictors of poor coronary collaterals. Third, there was
a synergistic effect on poor coronary collateral develop-
ment between hypertension and diabetes.
CKD and poor coronary collateral formation
Tissue hypoxia is a pathologic feature of many human
diseases like CAD, stroke, and kidney disease. In patients
with CKD, Chronic hypoxia in the kidney has been sug-









Number of diseased vessels 0.472(0.32-0.70)disease. It not only induces regulatory mechanisms
but also has a significant influence on gene expression
[22-24]. Several hypoxia-induced proteins such as
hypoxia-inducible factor (HIF), vascular endothelial
growth factor (VEGF), erythropoietin, and glucose trans-
porter 1 are reported to have protective effects in CKD
[25]. HIF and VEGF are also involved in angiogenesis
and associated with coronary collateral development
[26-28]. Furthermore, previous studies have reported
the association between CKD and poor coronary collat-
eral formation. Sezer M et al. stated that coronary collat-
eral formation is significantly poorer in patients with
renal failure (eGFR < 80 ml/min/1.73 m2) than in non-
uremic (eGFR ≧ 80 ml/min/1.73 m2) patients [13]. Xie
SL et al. also showed that lower eGFR is associated with
poorer coronary vessel development in patients experien-
cing mild to moderate renal insufficiency [14]. Similar to
previous studies, CKD patients with significant coronary
artery disease have high percentage of poor coronary
collaterals development. However, there is no literature
discussing about the predictor of poor coronary collat-
erals in the CKD population with SCAD.
The association between hypertension and coronary
collaterals
Microvascular rarefaction is known as a phenomenon
revealing there is smaller number of arterioles and ca-
pillaries in hypertensive subjects compared with non-
hypertensive subjects [29]. Recent studies have sug-
gested that capillary rarefaction in hypertension is
likely to be a primary or a very early structural ab-
normality. However, the detailed mechanism is still
not well understood. Impaired angiogenesis or micro-
vascular rarefaction could contribute to increased per-
ipheral resistance and raise blood pressure. There are
several theories explaining microvascular rarefaction
in hypertension. Rarefaction not only can antedate
the onset of hypertension but also occurs as a conse-
quence of prolonged elevation of blood pressure.
Primary rarefaction might result from impaired angio-
genesis and collateral network formation [30].irculation (good collateral group as reference group)
Multivariate analysis (forward)





0.004 2.672 (1.32-5.40) 0.006
0.847 - -
<0.001 0.402(0.26-0.62) <0.001
Table 4 Effect of diabetes and hypertension on the poor collateral development
Patient groups Poor collateral Good collateral OR(95% CI)a P value a
DM(−)/HTN(−) 15 (45.5%) 18 (54.5%) 1 -
DM(+)/HTN(−) or DM(−)/HTN(+) 45 (54.2%) 38 (45.8%) 1.42 (0.63-3.19) 0.395
DM(+)/HTN(+) 62 (72.1%) 24 (27.9%) 3.1 (1.35-7.12) 0.008
*HTN: hypertension; DM: diabetes; a Compared with nondiabetic and nonhypertensive group.
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ciation between hypertension and coronary collaterals
existing in clinical studies. Few studies in the past
suggest that there is a paradoxical increase in collat-
eral circulation in patients with hypertension and
CAD but Koerselman J et al. reported that hyperten-
sion is inversely associated with the presence and ex-
tent of coronary collaterals [31]. In our study,
hypertension is not only correlated with poor collat-
erals in the univariate analysis but also a significant
predictor of poor collateral formation in the multi-
variate analysis. These findings are similar to the
study of Koerselman J et al.’s study. In addition, re-
cent clinical research has also shown that long term
treatment of hypertension can prevent microvascular
rarefaction in hypertensive patients.
The association between diabetes and coronary
collaterals
Diabetic patients have a less favorable cardiovascular
outcome and higher mortality than non-diabetic patients
[32,33]. However, the precise mechanism is still not
clearly clarified. According to the literature, high glucose
levels could cause endothelial dysfunction and endothe-
lial cell is vital for coronary collateral formation [34]. In
addition, nitric oxide production, HIF-1, and vascular
endothelial growth factor (VEGF) expressions, which are
associated with angiogenesis, were also reported to be
impaired in hyperglycemic condition.[35,36]. These find-
ings all suggest that diabetes might lead to poor
coronary collateral development. In animal studies,
hyperglycemia reduces coronary collateral blood flow
through a nitric oxide-mediated mechanism in dog
model [37]. In human angiographic studies, Abaci A
et al. demonstrated that coronary collateral development
in the diabetes group was significantly poorer than in
the nondiabetic group [38]. In our study, we found dia-
betes is a significant predictor of poor collateral forma-
tion in the multivariate analysis.
Furthermore, we also found there was a synergistic
effect of hypertension and diabetes on the poor coron-
ary collateral formation. Hypertension is both a cause
and consequence of CKD. Blood pressure in CKD
patients is increased due to fluid overload and produc-
tion of vasoactive hormones via renin-angiotensin sys-
tem which might aggravate hypertension. Diabetes isalso another leading cause of CKD. Insulin and glu-
cose homeostasis are altered in the patients of end
stage renal disease and even in the early stages of
CKD, leading to insulin resistance by a variety of path-
ways [39,40]. Insulin resistance is reported to increase
with the progression of CKD, which also plays an im-
portant role in the pathogenesis of hypertension [41].
Hence, CKD might further potentiate hypertension
and diabetes and cause poor coronary collateral
formation.
Limitations of the present study
First, the collateral formation was assessed by coronary
angiography in this study. Measuring collateral flow
index by intravascular Doppler guidewire may provide a
more objective physiological measurement of collateral
grade. However, the invasiveness of intravascular ultra-
sound limits its use in large-scale studies. Second, since
this was only a clinical association study, potential
mechanisms were not fully elucidated.
Conclusions
Our data revealed that high percentages of CKD patients
have no coronary collaterals. Furthermore hypertension
and diabetes are both associated with poor coronary col-
laterals and have a negative synergistic effect on the col-
lateral development in the CKD population. Our data
might partially explain why CAD patients with CKD
have poor cardiovascular outcomes. These findings
could provide new insights on the risk stratification,
blood pressure and glucose control for CKD CAD
population.
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